Influence of genetic variants on how COCPs work in women who take them
Official title: Influence of genetic variants on the pharmacokinetics and pharmacodynamics of combined oral contraceptive pill users
Funded at Yale University · NIH-11333309 · Data updated 2026-11-12
This grant will study how genetic differences affect how combined oral contraceptives work in reproductive-age women.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | June 7, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $657,921 |
| NIH project number | 5R01HD111436-03 |
| Project ID | NIH-11333309 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women aged 21 and older who use combined oral contraceptives and are willing to contribute samples and medical information.
✕Less likely to help
Women who do not use COCPs or who decline participation would not benefit from this study.
What this research studies
Researchers at Yale will build a biobank of 700 COCP users to explore how genetics influence drug levels, effectiveness, and safety. The study aims to connect genetic data with real-world responses to combined estrogen-progestin pills, using new phenotypes tailored to steroid hormone medications. By identifying genetic factors that explain variation in drug handling, the team hopes to improve guidance on dosing and safety for women who rely on COCPs.
Why it matters
Potential benefit: If successful, the findings could lead to more personalized COCP choices and safer, more effective contraception for women.
How similar studies have gone: Previous pharmacogenomic work has shown genotype-guided dosing for some drugs, but this project addresses a gap in hormones and contraceptives with a new biobank.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Lazorwitz, Aaron — Yale University
- Study coordinator: Lazorwitz, Aaron
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding how broadly neutralizing antibodies may help HIV cure trials
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.